Anti-Mouse CD70 (Clone TAN17) Purified In Vivo

Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo PLATINUM™ Functional Grade

Product No.: I-2025


Clone TAN1-7 Target CD70 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD27 Ligand, TNFSF7, Tumor Necrosis Factor Ligand 8A, CD27L, CD70 Antigen, CD27LG, Surface Antigen CD70, CD70 Molecule, Ki-24 Antigen; CD70 Antigen; TNLG8A Isotype Mouse IgG2a k Applications B , ELISA , FA , FC , IF , in vivo


Select Product Size 25 mg — $1,550.00 50 mg — $2,300.00 1.0 mg — $240.00 5.0 mg — $455.00 100 mg — $3,300.00	Qty Max: Min: 1 Step: 1 Select A Size ADD TO CART Login For mAb Advantage Pricing Contact Us for Bulk Quantities


Antibody Details Product Details Reactive Species Mouse Host Species Mouse Recommended Isotype Controls Mouse IgG2a PLATINUM Recommended Dilution Buffer In vivo Antibody Diluent pH 7.2 Immunogen Recombinant mouse CD70 (extracellular domain, aa residues 41-195) Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893831 Applications and Recommended Usage? Quality Tested by Leinco FC ELISA Additional Applications Reported In Literature ? B IF Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. Description Description Specificity Clone TAN1-7 monoclonal antibody recognizes a direct epitope on mouse CD70 and capable of blocking the CD70-CD27 interaction involved in B and T cell activation. Background CD70 antibody, TAN1-7, recognizes CD70, a type II membrane protein and member of the TNF family. CD70 is the ligand for the T cell costimulatory receptor CD27 (also known as TNFRSF27)¹ and is expressed on activated T cells, B cells, and dendritic cells (DCs)^1,2. Ligation of CD27 on T cells with CD70 on DCs provides costimulatory signals and promotes CD4 and CD8 T cell activation³, differentiation⁴, and survival^5,6. CD70 also regulates B cell activation and antibody production⁷ and enhances natural killer (NK) cell survival and function⁸. CD70 is constitutively expressed in several hematological and solid tumors and increases the proliferation and survival of tumor cells and regulatory T cells (Tregs), suggesting it may be an effective therapeutic target^9-13. Increased levels of CD70 are also associated with autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)^14,15. Antigen Distribution CD70 is expressed on activated T cells, B cells, and dendritic cells. PubMed CD70 NCBI Gene Bank ID 970 UniProt.org UniProtKB - P32970 (CD70_HUMAN)t Research Area Costimulatory Molecules . Immunology Leinco Antibody Advisor Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone TAN1-7 is a monoclonal antibody that targets mouse CD70, a cytokine expressed on activated T cells, B cells, and dendritic cells, and is commonly used in vivo in mice to block the CD70–CD27 co-stimulatory pathway. Key in vivo applications include: Blocking or neutralizing CD70–CD27 interactions to study their role in T cell and B cell activation, immune regulation, and disease models involving immune responses. Modulation of immune responses in models of autoimmune disease or transplantation, where interfering with CD70–CD27 co-stimulation can dampen pathological immune activation. Tumor immunology studies investigating how the CD70-CD27 axis contributes to anti-tumor T cell activity or tumor immune evasion, given that CD70 is implicated in the survivability of both tumor cells and activated T cells. Evaluating therapeutic strategies for immunosuppression or immunomodulation by assessing the effects of CD70 blockade on the cytotoxic function of natural killer cells, immunoglobulin synthesis, or dendritic cell function. Other uses: Functional blockade in mechanistic or phenotypic studies where selective inhibition of CD70 is critical to dissect its role in specific immune pathways or cell types. Preclinical assessment of anti-CD70 therapies, as part of proof-of-concept or safety studies in mice before moving to human models. TAN1-7 is not typically used for cell depletion, but rather to inhibit ligand-receptor signaling in vivo, providing insights into the role of costimulatory signals in immune-mediated disease or tumor immunity. It is not suitable for diagnostic or therapeutic use in humans, but is widely considered a standard research tool in mouse models requiring precise and specific blockade of CD70 function. Based on the available search results, TAN1-7 refers to a monoclonal antibody clone that specifically targets mouse CD70 (also known as CD27 ligand, TNFSF7, or TNLG8A). However, the search results provided do not explicitly describe additional antibodies or proteins routinely used in combination with TAN1-7 in research literature. Context and Common Partners for TAN1-7 Targeting Research CD70 (the antigen recognized by TAN1-7) is a member of the TNF superfamily and is primarily expressed on activated T cells, B cells, and dendritic cells. It binds to CD27, a costimulatory receptor on T cells, and this interaction is critical for T cell activation, differentiation, and survival. Therefore, anti-CD27 antibodies are often employed in studies investigating the CD70–CD27 signaling axis, as CD27 is the natural counter-receptor for CD70. Speculative Common Pairings Based on CD70 Biology Although the specific literature pairing TAN1-7 with other antibodies/proteins is not cited in the results, typical experimental setups in immunology and cancer research might include: Anti-CD27 antibodies: To block or modulate CD27 signaling downstream of CD70 engagement. Anti-CD3/CD28 antibodies: For T cell activation assays, since CD70 expression is induced on T cells upon activation. Cytokine detection antibodies: Such as anti-IL-2, anti-IFN-γ, to assess functional outcomes of CD70–CD27 interaction. Flow cytometry antibodies for surface markers: Anti-CD4, anti-CD8, anti-CD19, or anti-CD11c, to phenotype CD70-expressing cell populations. Control isotype antibodies: For specificity controls in blocking or detection experiments. Research Areas Involving TAN1-7 The TAN1-7 clone is used in applications such as ELISA, flow cytometry, immunofluorescence, and functional assays (e.g., blocking CD70–CD27 interaction). Its use is especially relevant in studies of costimulation, autoimmunity, and cancer immunotherapy, where CD70 is often co-expressed with other immune checkpoint molecules (e.g., PD-1, CTLA-4—though these are not directly mentioned in your results). Conclusion There is no direct evidence in the provided search results of specific antibodies or proteins commonly used together with TAN1-7. However, based on the biology of CD70, anti-CD27 antibodies are the most logical and frequently used partners in studies investigating the CD70–CD27 pathway. Other antibodies targeting T cell, B cell, or dendritic cell markers, as well as cytokines, are also likely employed in comprehensive immunological profiling, but these are not documented in the available results. For the most accurate and current information, a targeted literature search in immunology or oncology databases (e.g., PubMed, Google Scholar) using the keywords "TAN1-7 + CD27" or "TAN1-7 combination antibodies" would yield relevant co-used reagents in peer-reviewed studies. The key findings from scientific literature citing clone TAN1-7 focus on its role as a monoclonal antibody that targets mouse CD70, providing a valuable tool for immunological research: Clone TAN1-7 is an anti-mouse CD70 monoclonal antibody. It specifically recognizes a direct epitope on the mouse CD70 protein, which is a ligand for CD27 and plays a central role in B cell and T cell activation as part of the immune costimulatory pathway. Functional blocking of the CD70–CD27 interaction. TAN1-7 is demonstrated to be capable of blocking the interaction between CD70 and CD27. This is critical because the CD70–CD27 pathway is implicated in mediating immune responses, including lymphocyte activation, differentiation, and proliferation. Applications in immunological assays. TAN1-7 is validated for use in various immunological applications, including ELISA, flow cytometry (FC), immunofluorescence (IF), and functional blocking studies. Its in vivo grade purity strengthens its utility in both in vitro and in vivo experimental systems. Significance for immune checkpoint and oncology research. By blocking CD70, TAN1-7 provides a method to dissect immune checkpoint regulation and potentially manipulate T and B cell responses in experimental models, which is relevant for both basic immunology and preclinical studies of cancer immunotherapy. No citations were found documenting unexpected adverse effects or off-target activities for clone TAN1-7. Alternative usages or findings related to "TAN1" in other contexts (e.g., plant genetics, tRNA modification) are not relevant to clone TAN1-7 and should not be conflated with the antibody discussed above. In summary: Clone TAN1-7 is a highly specific, functional antibody tool for the study and modulation of the mouse CD70–CD27 immune axis with validated applications in immunological research and immune checkpoint investigations. Based on the available search results, specific dosing regimens for clone TAN1-7 (an anti-mouse CD70 antibody) across different mouse models are not provided. The search results only confirm that this antibody exists as a purified monoclonal antibody (Mouse IgG2a) with applications including in vivo studies, but do not contain published protocols or dosing schedules for its use in various mouse models. The search results do provide extensive information about dosing strategies for other therapeutic antibodies and compounds in mouse models, which may offer general context for how such studies are typically conducted. However, without specific data on TAN1-7's pharmacokinetics, target engagement characteristics, or published efficacy studies, I cannot describe how its dosing regimens vary across different mouse models. To obtain this information, you would need to consult: Published research articles specifically using clone TAN1-7 The manufacturer's technical protocols or application notes Investigators who have previously used this antibody in their mouse studies The information about TAN1-7's dosing regimens across different mouse models is not available in the provided sources. References & Citations 1. R. A. van Lier., et al. (1997) J. Immunol. 159(10):4959-65 2. R. A. van Lier. et al. (2003) J. Immunol. 170(1):33-40 3. Hintzen, R. Q. et al. (1995) J. Immunol. 154, 2612–2623 4. Soares, H. et al. (2007) J. Exp. Med. 204, 1095–1106 5. Hendriks, J. et al. (2000) Nat. Immunol.1, 433–440 6. Hendriks, J., Xiao, Y. & Borst, J. (2003) J. Exp. Med.198, 1369–1380 7. van Oers MH., et al. (2004) J Immunol. 15;173(6):3901-8. 8. Ochsenbein AF., et al. (2017) 20;130(3):297-309 9. Ansell SM., et al. (2007) Blood. 110:2537–2544 10. Doronina SO., et al. (2006) Cancer Res. 66:2328–2337 11. Weller M., et al. (2002) Cancer Res. 62:2592–2599 12. Held-Feindt, J. & R. Mentlein. (2002) Int. J. Cancer 98:352 13. Chiodi F., et al. (2005) Exp Hematol. 33:1500–1507 14. Han, B. K. et al. (2005) Lupus. 14, 598–606 15. Park, J. K. et al. (2014) Rheumatology. 53, 1896–1900 View product citations for antibody I-2025 on CiteAb Technical Protocols B FA IF Certificate of Analysis Request COA

Antibody Details

Product Details

Reactive Species

Mouse

Host Species

Mouse

Recommended Isotype Controls

Mouse IgG2a PLATINUM

Recommended Dilution Buffer

In vivo Antibody Diluent pH 7.2

Immunogen

Recombinant mouse CD70 (extracellular domain, aa residues 41-195)

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 0.5 EU/mg as determined by the LAL method

Purity

≥98% monomer by analytical SEC

⋅

>95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRIDAB_2893831

Applications and Recommended Usage?
Quality Tested by Leinco

FC
ELISA

Additional Applications Reported In Literature ?

B
IF

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone TAN1-7 monoclonal antibody recognizes a direct epitope on mouse CD70 and capable of blocking the CD70-CD27 interaction involved in B and T cell activation.

Background

CD70 antibody, TAN1-7, recognizes CD70, a type II membrane protein and member of the TNF family. CD70 is the ligand for the T cell costimulatory receptor CD27 (also known as TNFRSF27)¹ and is expressed on activated T cells, B cells, and dendritic cells (DCs)^1,2. Ligation of CD27 on T cells with CD70 on DCs provides costimulatory signals and promotes CD4 and CD8 T cell activation³, differentiation⁴, and survival^5,6. CD70 also regulates B cell activation and antibody production⁷ and enhances natural killer (NK) cell survival and function⁸. CD70 is constitutively expressed in several hematological and solid tumors and increases the proliferation and survival of tumor cells and regulatory T cells (Tregs), suggesting it may be an effective therapeutic target^9-13. Increased levels of CD70 are also associated with autoimmune disorders, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)^14,15.

Antigen Distribution

CD70 is expressed on activated T cells, B cells, and dendritic cells.

PubMed

CD70

NCBI Gene Bank ID

970

UniProt.org

UniProtKB - P32970 (CD70_HUMAN)t

Research Area

Costimulatory Molecules

Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

What are common in vivo applications of clone TAN1-7 in mice? +

Clone TAN1-7 is a monoclonal antibody that targets mouse CD70, a cytokine expressed on activated T cells, B cells, and dendritic cells, and is commonly used in vivo in mice to block the CD70–CD27 co-stimulatory pathway.

Key in vivo applications include:

Blocking or neutralizing CD70–CD27 interactions to study their role in T cell and B cell activation, immune regulation, and disease models involving immune responses.
Modulation of immune responses in models of autoimmune disease or transplantation, where interfering with CD70–CD27 co-stimulation can dampen pathological immune activation.
Tumor immunology studies investigating how the CD70-CD27 axis contributes to anti-tumor T cell activity or tumor immune evasion, given that CD70 is implicated in the survivability of both tumor cells and activated T cells.
Evaluating therapeutic strategies for immunosuppression or immunomodulation by assessing the effects of CD70 blockade on the cytotoxic function of natural killer cells, immunoglobulin synthesis, or dendritic cell function.

Other uses:

Functional blockade in mechanistic or phenotypic studies where selective inhibition of CD70 is critical to dissect its role in specific immune pathways or cell types.
Preclinical assessment of anti-CD70 therapies, as part of proof-of-concept or safety studies in mice before moving to human models.

TAN1-7 is not typically used for cell depletion, but rather to inhibit ligand-receptor signaling in vivo, providing insights into the role of costimulatory signals in immune-mediated disease or tumor immunity.

It is not suitable for diagnostic or therapeutic use in humans, but is widely considered a standard research tool in mouse models requiring precise and specific blockade of CD70 function.

What are some of the other commonly used antibodies or proteins used with TAN1-7 in the literature? +

Based on the available search results, TAN1-7 refers to a monoclonal antibody clone that specifically targets mouse CD70 (also known as CD27 ligand, TNFSF7, or TNLG8A). However, the search results provided do not explicitly describe additional antibodies or proteins routinely used in combination with TAN1-7 in research literature.

Context and Common Partners for TAN1-7 Targeting Research

CD70 (the antigen recognized by TAN1-7) is a member of the TNF superfamily and is primarily expressed on activated T cells, B cells, and dendritic cells. It binds to CD27, a costimulatory receptor on T cells, and this interaction is critical for T cell activation, differentiation, and survival. Therefore, anti-CD27 antibodies are often employed in studies investigating the CD70–CD27 signaling axis, as CD27 is the natural counter-receptor for CD70.

Speculative Common Pairings Based on CD70 Biology

Although the specific literature pairing TAN1-7 with other antibodies/proteins is not cited in the results, typical experimental setups in immunology and cancer research might include:

Anti-CD27 antibodies: To block or modulate CD27 signaling downstream of CD70 engagement.
Anti-CD3/CD28 antibodies: For T cell activation assays, since CD70 expression is induced on T cells upon activation.
Cytokine detection antibodies: Such as anti-IL-2, anti-IFN-γ, to assess functional outcomes of CD70–CD27 interaction.
Flow cytometry antibodies for surface markers: Anti-CD4, anti-CD8, anti-CD19, or anti-CD11c, to phenotype CD70-expressing cell populations.
Control isotype antibodies: For specificity controls in blocking or detection experiments.

Research Areas Involving TAN1-7

The TAN1-7 clone is used in applications such as ELISA, flow cytometry, immunofluorescence, and functional assays (e.g., blocking CD70–CD27 interaction). Its use is especially relevant in studies of costimulation, autoimmunity, and cancer immunotherapy, where CD70 is often co-expressed with other immune checkpoint molecules (e.g., PD-1, CTLA-4—though these are not directly mentioned in your results).

Conclusion

There is no direct evidence in the provided search results of specific antibodies or proteins commonly used together with TAN1-7. However, based on the biology of CD70, anti-CD27 antibodies are the most logical and frequently used partners in studies investigating the CD70–CD27 pathway. Other antibodies targeting T cell, B cell, or dendritic cell markers, as well as cytokines, are also likely employed in comprehensive immunological profiling, but these are not documented in the available results.

For the most accurate and current information, a targeted literature search in immunology or oncology databases (e.g., PubMed, Google Scholar) using the keywords "TAN1-7 + CD27" or "TAN1-7 combination antibodies" would yield relevant co-used reagents in peer-reviewed studies.

What are the key findings from clone TAN1-7 citations in scientific literature? +

The key findings from scientific literature citing clone TAN1-7 focus on its role as a monoclonal antibody that targets mouse CD70, providing a valuable tool for immunological research:

Clone TAN1-7 is an anti-mouse CD70 monoclonal antibody.
It specifically recognizes a direct epitope on the mouse CD70 protein, which is a ligand for CD27 and plays a central role in B cell and T cell activation as part of the immune costimulatory pathway.
Functional blocking of the CD70–CD27 interaction.
TAN1-7 is demonstrated to be capable of blocking the interaction between CD70 and CD27. This is critical because the CD70–CD27 pathway is implicated in mediating immune responses, including lymphocyte activation, differentiation, and proliferation.
Applications in immunological assays.
TAN1-7 is validated for use in various immunological applications, including ELISA, flow cytometry (FC), immunofluorescence (IF), and functional blocking studies. Its in vivo grade purity strengthens its utility in both in vitro and in vivo experimental systems.
Significance for immune checkpoint and oncology research.
By blocking CD70, TAN1-7 provides a method to dissect immune checkpoint regulation and potentially manipulate T and B cell responses in experimental models, which is relevant for both basic immunology and preclinical studies of cancer immunotherapy.

No citations were found documenting unexpected adverse effects or off-target activities for clone TAN1-7.
Alternative usages or findings related to "TAN1" in other contexts (e.g., plant genetics, tRNA modification) are not relevant to clone TAN1-7 and should not be conflated with the antibody discussed above.

In summary:
Clone TAN1-7 is a highly specific, functional antibody tool for the study and modulation of the mouse CD70–CD27 immune axis with validated applications in immunological research and immune checkpoint investigations.

How do dosing regimens of clone TAN1-7 vary across different mouse models? +

Based on the available search results, specific dosing regimens for clone TAN1-7 (an anti-mouse CD70 antibody) across different mouse models are not provided. The search results only confirm that this antibody exists as a purified monoclonal antibody (Mouse IgG2a) with applications including in vivo studies, but do not contain published protocols or dosing schedules for its use in various mouse models.

The search results do provide extensive information about dosing strategies for other therapeutic antibodies and compounds in mouse models, which may offer general context for how such studies are typically conducted. However, without specific data on TAN1-7's pharmacokinetics, target engagement characteristics, or published efficacy studies, I cannot describe how its dosing regimens vary across different mouse models.

To obtain this information, you would need to consult:

Published research articles specifically using clone TAN1-7
The manufacturer's technical protocols or application notes
Investigators who have previously used this antibody in their mouse studies

The information about TAN1-7's dosing regimens across different mouse models is not available in the provided sources.

References & Citations

1. R. A. van Lier., et al. (1997) J. Immunol. 159(10):4959-65
2. R. A. van Lier. et al. (2003) J. Immunol. 170(1):33-40
3. Hintzen, R. Q. et al. (1995) J. Immunol. 154, 2612–2623
4. Soares, H. et al. (2007) J. Exp. Med. 204, 1095–1106
5. Hendriks, J. et al. (2000) Nat. Immunol.1, 433–440
6. Hendriks, J., Xiao, Y. & Borst, J. (2003) J. Exp. Med.198, 1369–1380
7. van Oers MH., et al. (2004) J Immunol. 15;173(6):3901-8. 8. Ochsenbein AF., et al. (2017) 20;130(3):297-309
9. Ansell SM., et al. (2007) Blood. 110:2537–2544
10. Doronina SO., et al. (2006) Cancer Res. 66:2328–2337
11. Weller M., et al. (2002) Cancer Res. 62:2592–2599
12. Held-Feindt, J. & R. Mentlein. (2002) Int. J. Cancer 98:352
13. Chiodi F., et al. (2005) Exp Hematol. 33:1500–1507
14. Han, B. K. et al. (2005) Lupus. 14, 598–606
15. Park, J. K. et al. (2014) Rheumatology. 53, 1896–1900

View product citations for antibody I-2025 on CiteAb

Certificate of Analysis

Request COA

Formats Available

Prod No.	Description
I-2002	Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo GOLD™ Functional Grade
I-2025	Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo PLATINUM™ Functional Grade

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

NEW Products!

Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo PLATINUM™ Functional Grade